REG - AstraZeneca PLC - AZN: Year-To-Date and Q3 2017 Results Announcement <Origin Href="QuoteRef">AZN.L</Origin> - Part 5
09/11/2017 07:08
- Part 5: For the preceding part double click ID:nRSI9871Vd
993 12 11 1,026 3 1
CVMD
Brilinta 224 (5) (4) 272 21 20 284 4 3
Farxiga 207 (13) (13) 250 21 20 285 14 11
Onglyza 154 3 3 150 (3) (3) 127 (15) (17)
Bydureon 153 8 8 146 (5) (5) 128 (12) (14)
Byetta 46 (16) (16) 43 (7) (7) 39 (9) (9)
Symlin 14 - - 11 (21) (21) 10 (9) (9)
Legacy:
Crestor 631 - 3 560 (11) (12) 580 4 2
Seloken/Toprol-XL 186 4 6 181 (3) (4) 160 (12) (14)
Atacand 75 (7) (6) 72 (4) (5) 80 11 8
Others 89 3 12 90 1 (3) 80 (11) (12)
Total CVMD 1,779 (2) - 1,775 - (1) 1,773 - (2)
Respiratory
Symbicort 677 (9) (7) 706 4 3 668 (5) (7)
Pulmicort 337 17 19 226 (33) (33) 242 7 5
Daliresp/Daxas 44 7 10 48 9 9 53 10 8
Tudorza/Eklira 37 3 6 34 (8) (8) 37 9 6
Duaklir 19 - - 16 (16) (15) 21 31 18
Bevespi 1 (67) (50) 3 n/m n/m 4 33 33
Others 66 (20) (19) 66 - (4) 67 2 4
Total Respiratory 1,181 (2) (1) 1,099 (7) (8) 1,092 (1) (3)
Other
Nexium 461 (6) (4) 595 29 28 469 (21) (22)
Synagis 230 (24) (24) 70 (70) (70) 153 n/m n/m
Losec/Prilosec 68 15 18 68 - (3) 66 (3) (6)
Seroquel XR 67 (43) (42) 95 42 38 62 (35) (36)
Movantik/Moventig 30 15 15 32 7 7 30 (6) (6)
FluMist/Fluenz - n/m n/m - - - 20 n/m n/m
Others 142 (42) (41) 213 50 51 191 (10) (11)
Total Other 998 (24) (22) 1,073 8 7 991 (8) (9)
TOTAL PRODUCT SALES 4,843 (8) (6) 4,940 2 1 4,882 (1) (3)
9 QUARTERLY PRODUCT SALES - 2016
The table below provides an analysis of sequential quarterly Product Sales, with Actual and CER growth rates reflecting
quarter-on-quarter growth.
Q1 2016$m Actual% CER% Q2 2016$m Actual% CER Q3 2016$m Actual% CER% Q4 2016$m Actual% CER%
%
Oncology
Tagrisso 51 183 200 92 80 82 133 45 44 147 11 11
Iressa 135 5 5 135 - (2) 125 (7) (8) 118 (6) (4)
Lynparza 44 22 22 54 23 23 58 7 7 62 7 9
Imfinzi - - - - - - - - - - - -
Legacy:
Faslodex 190 3 3 211 11 9 207 (2) (2) 222 7 9
Zoladex 178 (10) (8) 204 15 8 199 (2) (2) 235 18 11
Casodex 62 (2) (6) 63 2 - 62 (2) (5) 60 (3) (2)
Arimidex 57 (5) (5) 62 9 7 56 (10) (13) 57 2 5
Others 21 (22) (22) 27 29 12 27 - 4 29 7 -
Total Oncology 738 3 3 848 15 12 867 2 2 930 7 7
CVMD
Brilinta 181 4 5 214 18 16 208 (3) (2) 236 13 15
Farxiga 165 9 10 211 28 26 220 4 4 239 9 9
Onglyza 211 10 12 191 (9) (11) 169 (12) (11) 149 (12) (11)
Bydureon 135 (13) (16) 156 16 14 145 (7) (6) 142 (2) (1)
Byetta 62 (14) (14) 76 23 21 61 (20) (19) 55 (10) (10)
Symlin 5 (64) (64) 10 n/m n/m 11 10 10 14 27 27
Legacy:
Crestor 1,156 (13) (13) 926 (20) (21) 688 (26) (26) 631 (8) (7)
Seloken/Toprol-XL 185 16 11 189 2 - 185 (2) (2) 178 (4) (2)
Atacand 71 (17) (15) 89 25 22 74 (17) (19) 81 9 14
Others 121 (9) (16) 106 (12) (11) 84 (21) (19) 86 2 -
Total CVMD 2,292 (7) (7) 2,168 (5) (7) 1,845 (15) (15) 1,811 (2) (1)
Respiratory
Symbicort 749 (13) (12) 803 7 6 697 (13) (13) 740 6 8
Pulmicort 310 13 14 239 (23) (23) 224 (6) (6) 288 29 31
Daliresp/Daxas 31 (3) (3) 40 29 29 42 5 5 41 (2) (2)
Tudorza/Eklira 39 (17) (17) 48 23 21 47 (2) - 36 (23) (23)
Duaklir 13 8 8 17 31 31 14 (18) (18) 19 36 43
Bevespi - - - - - - - - - 3 n/m n/m
Others 65 - (3) 79 22 18 86 9 12 83 (3) 1
Total Respiratory 1,207 (6) (6) 1,226 2 1 1,110 (9) (9) 1,210 9 10
Other
Nexium 463 (18) (18) 562 21 20 516 (8) (9) 491 (5) (4)
Synagis 244 (11) (11) 27 (89) (89) 104 n/m n/m 302 n/m n/m
Losec/Prilosec 75 (3) (4) 70 (7) (9) 72 3 4 59 (18) (17)
Seroquel XR 202 (16) (16) 225 11 11 190 (16) (16) 118 (38) (37)
Movantik/Moventig 17 13 13 23 35 35 25 9 9 26 4 4
FluMist/Fluenz 5 (97) (97) 6 20 20 26 n/m n/m 67 n/m n/m
Others 322 (15) (7) 314 (2) (4) 270 (14) (16) 246 (9) (8)
Total Other 1,328 (24) (22) 1,227 (8) (9) 1,203 (2) (3) 1,309 9 10
TOTAL PRODUCT SALES 5,565 (10) (10) 5,469 (2) (3) 5,025 (8) (8) 5,260 5 6
10 QUARTERLY PRODUCT SALES - 2015
The table below provides an analysis of sequential quarterly Product Sales, with Actual and CER growth rates reflecting
quarter-on-quarter growth.
Q1 2015$m Actual% CER% Q2 2015$m Actual% CER Q3 2015$m Actual% CER% Q4 2015$m Actual% CER%
%
Oncology
Tagrisso - - - - - - - - - 18 n/m n/m
Iressa 144 (4) - 129 (10) (8) 141 9 10 129 (9) (7)
Lynparza 9 n/m n/m 21 133 133 28 33 33 36 29 29
Imfinzi - - - - - - - - - - - -
Legacy:
Faslodex 161 (12) (6) 172 7 8 186 8 8 185 (1) 1
Zoladex 194 (15) (9) 215 11 11 209 (3) - 198 (5) (2)
Casodex 70 (5) 1 69 (1) - 65 (6) (4) 63 (3) (1)
Arimidex 62 (9) (5) 64 3 7 64 - - 60 (6) (5)
Others 34 (13) (10) 37 9 9 35 (5) - 27 (23) (16)
Total Oncology 674 (9) (4) 707 5 6 728 3 5 716 (2) -
CVMD
Brilinta 131 (2) 3 144 10 13 170 18 19 174 2 4
Farxiga 76 (19) (18) 129 70 75 135 5 5 152 13 14
Onglyza 183 (9) (5) 208 14 15 203 (2) (2) 192 (5) (5)
Bydureon 123 - 8 140 14 11 162 16 13 155 (4) (1)
Byetta 90 30 35 82 (9) (9) 72 (12) (12) 72 - 1
Symlin 16 60 60 13 (19) (19) 5 (62) (62) 14 n/m n/m
Legacy:
Crestor 1,167 (16) (13) 1,310 12 14 1,218 (7) (7) 1,322 9 9
Seloken/Toprol-XL 194 11 22 184 (5) (4) 172 (7) (3) 160 (7) -
Atacand 95 (19) (11) 99 4 9 78 (21) (19) 86 10 13
Others 155 (7) 7 143 (8) (7) 132 (8) (7) 133 1 4
Total CVMD 2,230 (10) (6) 2,452 10 12 2,347 (4) (4) 2,460 5 7
Respiratory
Symbicort 845 (14) (9) 842 - 2 848 1 1 859 1 3
Pulmicort 286 6 11 232 (19) (17) 222 (4) (6) 274 23 26
Daliresp/Daxas 7 n/m n/m 32 n/m n/m 33 3 3 32 (3) (3)
Tudorza/Eklira 30 n/m n/m 55 83 90 58 5 5 47 (19) (19)
Duaklir 2 n/m n/m 5 n/m n/m 8 60 60 12 50 50
Bevespi - - - - - - - - - - - -
Others 73 (4) 12 59 (19) (20) 61 3 3 65 7 11
Total Respiratory 1,243 (7) (2) 1,225 (1) 1 1,230 - - 1,289 5 6
Other
Nexium 644 (23) (20) 647 - 3 641 (1) (2) 564 (12) (10)
Synagis 204 (50) (50) 66 (68) (68) 117 77 77 275 135 135
Losec/Prilosec 96 (13) (8) 85 (11) (9) 82 (4) (5) 77 (6) (2)
Seroquel XR 262 (15) (13) 264 1 4 258 (2) (2) 241 (7) (6)
Movantik/Moventig 3 n/m n/m 1 (67) (67) 10 n/m n/m 15 50 50
FluMist/Fluenz 7 (95) (94) 14 n/m n/m 76 n/m n/m 191 n/m n/m
Others 385 12 16 375 (3) 1 361 (4) 2 379 5 2
Total Other 1,601 (25) (24) 1,452 (9) (7) 1,545 6 8 1,742 13 13
TOTAL PRODUCT SALES 5,748 (14) (10) 5,836 2 3 5,850 - 1 6,207 6 7
Shareholder Information
Announcement of full year and final quarter 2017 results 2 February 2018
Announcement of first quarter 2018 results 18 May 2018
Annual General Meeting 18 May 2018
Future dividends will normally be paid as follows:
First interim Announced with half-year and second-quarter results and paid in September
Second interim Announced with full-year and fourth-quarter results and paid in March
The record date for the second interim dividend for 2017, payable on 19 March 2018, will be 16 February 2018. The
ex-dividend date will be 15 February 2018.
The record date for the first interim dividend for 2018, payable on 10 September 2018, will be 10 August 2018. The
ex-dividend date will be 09 August 2018.
Trademarks of the AstraZeneca group of companies and of companies other than AstraZeneca appear throughout this document in
italics. AstraZeneca, the AstraZeneca logotype and the AstraZeneca symbol are all trademarks of the AstraZeneca group of
companies. Trademarks of companies other than AstraZeneca that appear in this document include Duaklir Genuair, Duaklir,
Eklira, and Tudorza, trademarks of Almirall, S.A.; Epanova, a trademark of Chrysalis Pharma AG.; Synagis, owned by
AstraZeneca or AbbVie Inc. (depending on geography); Zavicefta, a trademark of Pfizer Inc.; and Zomig, a trademark of
Grünenthal GmbH.
Addresses for Correspondence
Registered Office1 Francis Crick AvenueCambridge Biomedical CampusCambridgeCB2 0AAUK Registrar andTransfer OfficeEquiniti LimitedAspect HouseSpencer RoadLancingWest SussexBN99 6DAUK Swedish Central Securities DepositoryEuroclear Sweden ABPO Box 191SE-101 23 StockholmSweden US DepositaryCitibank Shareholder ServicesPO Box 43077ProvidenceRI 02940-3077USA
Tel: +44 (0)20 3749 5000 Tel (Freephone in UK):0800 389 1580 Tel (outside UK): Tel: +46 (0)8 402 9000 Tel: (toll free in the US)+1 (888) 697 8018 Tel: (outside the US)+1 (781) 575 4555 citibank@shareholders-online.com
+44 (0)121 415 7033
Cautionary Statements Regarding Forward-Looking Statements
_______________________________________________________________________________________
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act
1995, we are providing the following cautionary statement:
This document contains certain forward-looking statements with respect to the operations, performance and financial
condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or
other financial or other measures. Although we believe our expectations are based on reasonable assumptions, any
forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that
could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements
reflect knowledge and information available at the date of preparation of this document and AstraZeneca undertakes no
obligation to update these forward-looking statements. We identify the forward-looking statements by using the words
'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could
cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond
our control, include, among other things: the loss or expiration of, or limitations to, patents, marketing exclusivity or
trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IP
rights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any
failure by third parties to supply materials or services; the risk of failure of outsourcing; the risks associated with
manufacturing biologics; the risk that R&D will not yield new products that achieve commercial success; the risk of delay
to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and
acquisitions, including licensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic
competition; the impact of competition, price controls and price reductions; the risks associated with developing our
business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintaining
regulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect
on future commercial prospects; the risk of failure to successfully implement planned cost reduction measures through
productivity initiatives and restructuring programmes; the risk of failure of critical processes affecting business
continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve
strategic priorities or to meet targets or expectations; the risk of substantial adverse litigation/government
investigation claims and insufficient insurance coverage; the risk of substantial product liability claims; the risk of
failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and
regulations relating to anti-competitive behaviour; the impact of increasing implementation and enforcement of more
stringent anti-bribery and anti-corruption legislation; taxation risks; exchange rate fluctuations; the risk of an adverse
impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmental liabilities;
the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of
failing to attract and retain key personnel and to successfully engage with our employees; the risk of misuse of social
medial platforms and new technology; and the risk of failure of information technology and cybercrime. Nothing in this
presentation / webcast should be construed as a profit forecast.
This information is provided by RNS
The company news service from the London Stock ExchangeRecent news on AstraZeneca
See all newsRCS - LHH - LHH, EZRA's AI Leadership Transformation Program
AnnouncementREG - AstraZeneca PLC - Baxdrostat met primary endpoint in Bax24 Ph3 trial
AnnouncementREG - AstraZeneca PLC - Datroway improved OS and PFS in TROPION-Breast02
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Enhertu improved IDFS in early BC in DB-05
Announcement